A Phase I, Open-label, Multi-center, Single Dose, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of LCI699 in Subjects With Varying Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Osilodrostat (Primary)
- Indications Cushing syndrome; Renal impairment
- Focus Pharmacokinetics
- Sponsors Novartis
- 05 Oct 2016 Status changed from recruiting to completed.
- 05 Feb 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.
- 05 Feb 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.